LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for ...

Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug ...

J&J executives have said they expect the therapy, Inlexzo, to become a future blockbuster and generate sales that ...

The drugmaker’s new CEO said the moves will help the company be more agile as it deals with competition in the obesity market ...

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.

Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into ...

The Bristol Myers-partnered bispecific antibody kept small cell lung cancer under control in participants enrolled in a Phase ...

Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with ...

One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset ...

A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often ...

The venture arms of Merck KGaA and Novartis are among the investors involved in raising $67 million for NRG Therapeutics, ...

Modern obesity trials are inherently complex, but the momentum behind these therapeutics has never been greater. With over ...